Sana Biotechnology Past Earnings Performance
Past criteria checks 0/6
Sana Biotechnology's earnings have been declining at an average annual rate of -3.2%, while the Biotechs industry saw earnings growing at 19.7% annually.
Key information
-3.2%
Earnings growth rate
82.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -72.1% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05Revenue & Expenses Breakdown
How Sana Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -245 | 73 | 223 |
31 Mar 24 | 0 | -309 | 73 | 281 |
31 Dec 23 | 0 | -283 | 73 | 254 |
30 Sep 23 | 0 | -276 | 76 | 246 |
30 Jun 23 | 0 | -362 | 63 | 284 |
31 Mar 23 | 0 | -320 | 61 | 248 |
31 Dec 22 | 0 | -269 | 58 | 204 |
30 Sep 22 | 0 | -300 | 56 | 232 |
30 Jun 22 | 0 | -298 | 54 | 232 |
31 Mar 22 | 0 | -207 | 53 | 135 |
31 Dec 21 | 0 | -356 | 50 | 275 |
30 Sep 21 | 0 | -358 | 47 | 266 |
30 Jun 21 | 0 | -327 | 41 | 230 |
31 Mar 21 | 0 | -433 | 34 | 336 |
31 Dec 20 | 0 | -285 | 28 | 232 |
30 Sep 20 | 0 | -215 | 25 | 174 |
31 Dec 19 | 0 | -131 | 22 | 102 |
Quality Earnings: SANA is currently unprofitable.
Growing Profit Margin: SANA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SANA is unprofitable, and losses have increased over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare SANA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SANA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: SANA has a negative Return on Equity (-72.1%), as it is currently unprofitable.